EGFR and lung adenocarcinoma: These findings further confirm the involvement of JAK3 in the development of resistance to EGFR-TKIs in EGFR-sensitive mutant lung adenocarcinoma, thereby offering a novel therapeutic strategy for addressing EGFR-TKI resistance.